Clinical trials: Depression / Major Depressive Disorder
Bipolar Depression, Suicidal Ideas
Sequential Therapy for the Treatment of Severe Bipolar Depression.
NeuroRx is developing NRX-101, a fixed-dose combination oral capsule composed of d-cycloserine (DCS) and lurasidone for the maintenance of remission from Severe Bipolar Depression with Acute Suicidal Ideation (C-SSRS level 4 or…
- Conditions
- Bipolar Depression, Suicidal Ideas, Suicidal Ideation, Suicide, Attempted
- Trial name
- STABIL-B (NCT02974010)
- Testing
- NRX-101 Oral Capsule, Lurasidone Oral Capsule, Ketamine Intravenous Infusion
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- NeuroRx, Inc.
Depression, Major Depressive Disorder
Flavanol Augmentation for Antidepressant Non-Responsive Late Life Depression
The goal of this proposal is to conduct the first pilot study of whether consuming flavanol supplements will augment the cognitive and mood benefits of antidepressant medication in older adults with Late LifeDepression (LLD).
- Trial name
- Flavanol (NCT02943096)
- Testing
- CocoaVia
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- New York State Psychiatric Institute
Depressive Disorder, Major
A Study in Adult Patients With Major Depressive Disorder
The purpose of this study is to assess whether LY2216684 is superior to placebo in the treatment of adult patients with major depressive disorder.
- Trial name
- NCT00795821
- Testing
- LY2216684
- Where
- 37 sites in United States, Argentina and 3 more
- Volunteers
- 495 people
- Sponsor
- Eli Lilly and Company
Dysthymic Disorder, Depressive Disorder NOS
Duloxetine for Chronic Depression: a Double-blind Study
The investigators are studying a new antidepressant medicine, duloxetine, for the treatment of people with chronic depression. Duloxetine (trade name Cymbalta) was recently approved by the FDA for the treatment of major…
- Trial name
- NCT00360724
- Testing
- Duloxetine (Cymbalta)
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- New York State Psychiatric Institute
Depressive Disorder, Major
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)
Evaluating the efficacy of vortioxetine 10 mg/day and 20 mg/day versus placebo on depressive symptoms in adolescents (age ≥12 and ≤17 years) with a DSM-5™ (Diagnostic and Statistical Manual of Mental Disorders, 5th edition)…
- Trial name
- NCT02709746
- Testing
- Vortioxetine 10 mg/day, Vortioxetine 20 mg/day, Fluoxetine 20 mg/day
- Where
- 124 sites in United States, Bulgaria and 17 more
- Volunteers
- 784 people
- Sponsor
- H. Lundbeck A/S
Depressive Disorder, Depression
A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial
To compare the efficacy of brexpiprazole (flexible dose) with placebo as adjunctive therapy to an assigned open label antidepressant therapy (ADT) in the proposed subject population with MDD.
- Conditions
- Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders
- Trial name
- NCT01727726
- Testing
- Brexpiprazole, Seroquel XR
- Where
- 76 sites in United States, Canada and 5 more
- Volunteers
- 2,182 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Irritable Bowel Syndrome
An Open-Label Trial of Duloxetine for the Treatment of Irritable Bowel Syndrome
We hypothesize that duloxetine treatment will be associated with improvement in symptoms of IBS, particularly abdominal pain, in individuals without comorbid major depressive disorder.
- Trial name
- NCT00401258
- Testing
- duloxetine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mclean Hospital
Depression, Unipolar, Mental Health Disorder
Reaching and Engaging Depressed Senior Center Clients (REDS)
The purpose of this study is to test the feasibility of two types of group therapy sessions. The research is being done because the researchers are trying to learn if these approaches could be used by therapist in the community…
- Trial name
- REDS (NCT03246789)
- Testing
- Engage-M, Wellness in Mind and Body
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Weill Medical College of Cornell University
Alcoholism, Depression
Pharmacological Intervention Project (Fluoxetine)
This is a large scale study involving fluoxetine (Prozac) versus a placebo in the treatment of adolescents with alcohol use disorder (AUD) and major depression (MDD).
- Trial name
- FIDAA (NCT00027378)
- Testing
- fluoxetine (Prozac)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Pittsburgh
Depression
Effects of Adding Motivational Interviewing to Antidepressant Treatment for Hispanic Adults With Depression
This study will evaluate the effectiveness of adding motivational interviewing to antidepressant treatment for major depressive disorder in Hispanic adults.
- Trial name
- NCT00564278
- Testing
- Standard antidepressant therapy (SADT), Motivational antidepressant therapy (MADT)
- Where
- United States
- Volunteers
- 217 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder
iCBT With TMS in Patients With MDD
Major Depressive Disorder (MDD) is a common mental health diagnosis. While there are many approaches to the treatment of MDD, current treatments of MDD often do not substantially reduce depressive symptoms among those in need of…
- Trial name
- NCT05988619
- Testing
- Transcranial Magnetic Stimulation, Internet-Based Cognitive Behavioral Therapy, Psychoeducation
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of California, Los Angeles
Unipolar Depression, Bipolar Depression
The Antidepressant Efficacy of the Anticholinergic Scopolamine
A previous study showed that the intravenous administration of scopolamine produces antidepressant effects. This study is designed to determine if other routes of administration of scopolamine produce antidepressant effects.
- Trial name
- NCT00369915
- Testing
- Scopolamine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Institute of Mental Health (NIMH)
Major Depressive Disorder
Safety and Efficacy Study Comparing ETS6103 With Amitriptyline in the Treatment of Major Depressive Disorder (MDD)
To demonstrate that the antidepressant activity of ETS6103 is not inferior to amitriptyline in subjects who have an unsatisfactory response to / are resistant to treatment with SSRIs.
- Trial name
- ETS6103-003 (NCT02014363)
- Testing
- ETS6103 (low dose), ETS6103 (high dose), Amitriptyline
- Where
- United Kingdom
- Volunteers
- 164 people
- Sponsor
- e-Therapeutics PLC
Depression, Unipolar
Repeated Neurocognitive Measurements in Depressed Patients
In this project, we will A) track the functioning of a collection of potential neurobiological targets for depression over time, B) examine how fluctuations in the functioning of those targets relates to real-world functioning…
- Trial name
- NCT04916548
- Testing
- Intravenous Ketamine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Rebecca Price
MDD
Maintenance Transcranial Magnetic Stimulation in Major Depressive Disorder
This an open label study using a FDA-cleared TMS stimulation protocols which will be used to treat patients who have responded or remitted from depression using acute clinical TMS therapy at the University of Missouri-Columbia…
- Trial name
- NCT04076644
- Testing
- TMS treatment
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Missouri-Columbia
Major Depressive Disorder
Efficacy of Adjunctive Exercise for the Behavioral Treatment of Major Depression
Major depressive disorder (MDD) is the leading cause of disability in the developed world and is associated with lost productivity, increased health care utilization, and mortality.
- Trial name
- NCT02176408
- Testing
- Behavioral Activation, Exercise Intervention, Stretching Intervention
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Boston University Charles River Campus
Major Depressive Disorder
A 12-Week, Placebo Controlled Trial of Ziprasidone as Monotherapy for Major Depressive Disorder
This is a study on the effectiveness, tolerability and safety of oral ziprasidone as monotherapy in patients with major depressive disorder (MDD).
- Trial name
- Geodon (NCT00555997)
- Testing
- Ziprasidone
- Where
- 7 sites in United States
- Volunteers
- 120 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Ketamine in Adolescents With Treatment-Resistant Depression
This study will test the use of ketamine for treatment of depression in adolescents that have not responded to other treatments. We will also examine neurobiological mechanisms of treatment.
- Trial name
- NCT02078817
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Minnesota
Nicotine Dependence, Major Depressive Disorder
Behavioral Activation and Varenicline for Smoking Cessation in Depressed Smokers
Persons who struggle with depression smoke at high rates and experience low quit rates in treatment. The best way to improve cessation treatment for this underserved population remains unknown.
- Trial name
- NCT02378714
- Testing
- Varenicline, BASC, Standard treatment
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- Northwestern University
Serious Mental Illness, Schizophrenia
Fixed Dose Intervention Trial of New England Enhancing Survival in SMI Patients
Patients with severe mental illness (SMI) die younger than persons in the general population. Much of the excess mortality for SMI patients is attributable to cardiovascular disease, and is exacerbated by treatment with…
- Conditions
- Serious Mental Illness, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- FITNESS (NCT02188121)
- Testing
- Simvastatin, Losartan
- Where
- United States
- Volunteers
- 227 people
- Sponsor
- Mclean Hospital